A post at MassGenomics summarizes a lecture that the Mayo Clinic's David Smith gave on how the institution is using next-gen sequencing in clinical application. For the most part, Mayo is using it for rare variant detection in tumors, detecting mutations in mitochondrial DNA, and transcriptional profiling.